ReviewFrontiers in psychiatry2026
Identifying psychiatric comorbidities that occur following the introduction of hormonal contraception: a scoping review.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hormonal contraceptives are widely used by women of reproductive age, yet concerns persist regarding their potential effects on mental health. Although mood-related side effects are frequently reported, their prevalence, clinical significance, and variation across formulations remain unclear. This scoping review examined associations between hormonal contraception and psychiatric outcomes, focusing on depressive symptoms, anxiety, and other mental health disorders. Methods: A comprehensive search of four major databases identified peer-reviewed studies published between 2014 and 2024. Forty-six studies met inclusion criteria, encompassing observational cohorts, cross-sectional surveys, and clinical trials. Study quality was assessed using the Joanna Briggs Institute checklist. Random-effects meta-analysis and subgroup analyses were conducted by hormonal class and psychiatric outcome. Results: Pooled analyses indicated a small but statistically significant association between hormonal contraceptive use (particularly progestin-only methods) and increased depressive symptoms (RR = 1.24, 95% CI 1.08-1.42; I² = 97.7%). For suicidality, cohort studies reported estimates ranging from HR = 1.97 in younger users to OR = 1.57 with long-term progestin-only use, although the pooled estimate across four studies was imprecise (RR = 1.20, 95% CI 0.65-2.21; I² = 98%). Evidence for anxiety and other psychiatric outcomes was inconsistent; four anxiety-focused studies yielded a non-significant pooled effect (RR = 1.08, 95% CI 0.83-1.40; τ² = 0.13). Methodological heterogeneity, particularly in outcome measurement and control for confounding, was a frequent limitation. Discussion: These findings suggest that hormonal contraception may contribute to adverse psychiatric outcomes in a subset of users. Integrating mental health screening into contraceptive counseling and conducting well-designed prospective studies with standardized psychiatric measures are essential for guiding safer, more tailored contraceptive prescribing practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.